Climodien® (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints

Climacteric

Volumn 4, Issue 4, 2001, Pages 332-342

  Graser T ^a   Romer T ^b   Wiedey, K D ^c   Janaud, A ^d  

^a BAYER PHARMA AG   (Germany)

^b Evangelisches Krankenhaus Koln Weyertal   (Germany)

^c ECRON   (Germany)

^d NONE   (France)

Author keywords

Climodien; Continuous combined hormone replacement therapy; Efficacy; Menopause; Safety

Indexed keywords

DIENOGEST PLUS ESTRADIOL VALERATE; ESTRADIOL DERIVATIVE; ESTRADIOL PLUS NORETHISTERONE ACETATE; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL; DIENOGEST; DRUG DERIVATIVE; ESTRADIOL; ESTRADIOL VALERATE; FOLLITROPIN; LIPOPROTEIN; NANDROLONE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; TABLET; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECHOGRAPHY; ENDOMETRIUM; EUROPE; HORMONE SUBSTITUTION; MIDDLE AGED; OSTEOLYSIS; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; UTERUS BLEEDING;

AGED; BONE RESORPTION; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENDOMETRIUM; ESTRADIOL; EUROPE; FEMALE; FOLLICLE STIMULATING HORMONE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; LIPOPROTEINS; MIDDLE AGED; NANDROLONE; PATIENT SATISFACTION; POSTMENOPAUSE; TRIGLYCERIDES; UTERINE HEMORRHAGE;

EID: 0035542898     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.4.4.332.342     Document Type: Article

References (29)

1. Menopause and postmenopause
2. Hormone therapy to prevent disease and prolong life in postmenopausal women
3. Postmenopausal hormonal replacement therapy
4. Hormone treatment of postmenopausal women
5. Hormonal treatment for the climacteric: Alleviation of symptoms and prevention of postmenopausal disease
6. Estrogens, lipids and cardiovascular disease: No easy answer
7. European and North American experience with HRT for the prevention of osteoporosis
8. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
9. Risk of endometrial cancer following estrogen replacement with and without progestins
10. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy
11. Effects of hormone replacement therapy on endometrial histology in postmenopausal women
12. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women
13. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - A doseranging study
14. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest® for continuous combined hormone replacement therapy in postmenopausal women
15. Introduction: Structure-function relationships, metabolism, pharmacokinetics and potency of progestins
16. Organ targeting with the oral progestin dienogest
17. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins
18. Adverse drug reactions. A critical review
19. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices
20. Progestogens: Therapeutic and adverse effects in early postmenopausal women
21. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment
22. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient
23. Combined continuous hormone replacement therapy: A critical review
24. The lipid research clinics coronary primary prevention trial results: The relationship or reduction in incidence of coronary heart disease to cholesterol
25. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
26. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
27. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
28. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern